CSIMarket
 
Odonate Therapeutics Inc   (ODT)
Other Ticker:  
 
 
Price: $0.0000 $0.00 %
Day's High: 0.00 Week Perf:
Day's Low: $ 0.00 30 Day Perf:
Volume (M): 0 52 Wk High: $ 0.00
Volume (M$): $ 0 52 Wk Avg: $0.00
Open: $0.00 52 Wk Low: $0.00



 Market Capitalization (Millions $) -
 Shares Outstanding (Millions) 38
 Employees 10
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -102
 Cash Flow (TTM) (Millions $) -93
 Capital Exp. (TTM) (Millions $) 0

Odonate Therapeutics Inc

We were incorporated in the State of Nevada on November 16, 2009 under the name “Online Disruptive Technologies, Inc.” with authorized capital of 500,000,000 shares of common stock with a par value of $0.001 per share and 20,000,000 shares of preferred stock with a par value of $0.001 per share. On March 24, 2010, we entered into a share purchase agreement with Benjamin Cherniak, whereby we acquired all of the issued and outstanding shares of RelationshipScoreboard.com Entertainment, Inc. (“RSE”) in consideration for the issuance of 16,000,000 of our common shares. RSE was incorporated in the State of Nevada on November 16, 2009. There were no related party interests in the acquisition of RSE.

The Savicell™ platform is a blood test designed for the early detection of disease. It is a broad platform with applications for cancer, autoimmune diseases, and infectious diseases. While our focus initially is on early diagnosis of disease, we believe our technology may have additional applications in drug response monitoring for therapies that impact immune response. Immunotherapy, both for treating cancer and autoimmune diseases, is an example where metabolic shift profiles could indicate response to drug treatment.

Initially, Savicell is focused on the multibillion-dollar cancer diagnosis market. Savicell deploys Well-Shield™ technology, a Liquid ImmunoBiopsy™ diagnostic platform. In contrast to existing technologies that evaluate secretions of cancer cells, Well-Shield’s ImmunoBiopsy platform receives data directly from the immune system. Importantly, Well-Shield is different in that it is a functional test measuring the metabolic activation profile of the immune system as an indicator of disease status. As an immune system test, it is inherently suited for early detection.

The technology has now received intellectual property protection with a patent approved in the United States, China, Japan and Europe. Furthermore, the patent process is ongoing in several other countries.

Disease intrusion and cell malformation, including cancer, are first detected by the immune system, which energizes to rid the body of the malignancy. The initial immune response to disease is intricate, deploying different metabolic pathways and subtypes of cells. The Well-ShieldTM technology is designed to detect and interpret these differential metabolic responses.

The Savicell vision is to develop and commercialize a line of patient-friendly blood tests that enable early diagnosis, staging, and monitoring, thereby saving lives and ensuring appropriate treatment. Cancer is our initial focus.

The need for early diagnosis

Cancer cases are increasing, with more than 20 million new cases predicted in 2025, compared to 12 million in 2008. Early detection is very important because it can improve outcomes. Typically, more treatment options are available when cancer is diagnosed early, and survival improves. In the United States, the five-year survival rate improves by at least four times with early diagnosis and before cancer has spread. Unfortunately, to date, the majority of cancer patients are diagnosed at later stages.

While surgical biopsies are the norm, they are invasive and expensive. The need for simpler and more efficient processes for cancer detection has incentivized some 38 companies in the United States to work on creating liquid biopsies. In a 2015 report, investment bank Piper Jaffray valued the potential market for liquid biopsies at $29 billion in the United States alone.

Using technologies based on circulating tumor cells, exosomes, and circulating tumor nucleic acids, liquid biopsy companies are making progress in developing products that have advantages versus current technologies. However, it appears more likely that these types of liquid biopsy technologies best support late stage cancers, with technical challenges remaining for early-stage cancers and early cancer screening.

In contrast, the Well-Shield patented ImmunoBiopsy platform is unique in the Liquid Biopsy market. And we believe that as an immune system functional test it is inherently better suited for early detection.

Product focus

Savicell conducted clinical work for tests specific to breast and lung cancers in multiple medical centers. We had encouraging early reviews of our breast cancer and lung cancer analyses albeit on relatively small sample sizes. Specifically, we distinguished between breast cancer patients and healthy donors, and lung cancer patients and healthy donors, with high sensitivity and specificity of greater than 95% in both cancers. In addition, we were able to show that there is a metabolic profile difference between other breast disease donors and breast cancer donors and between COPD (chronic obstructive pulmonary disease) donors and lung cancer donors.

Based on this early potential, Savicell has decided to focus our resources on lung cancer as our lead product. We are working to increase the population size of the lung cancer clinical test and continue to fine-tune a predictive algorithm to identify lung cancer. Early results of this effort generated promising cross-validation of 72 donors from our clinical study. This cohort includes 36 diseased donors, together with a control group of 36 age- and sex-matched healthy donors. In practice this means that every lung cancer (patient) donor in the cohort was matched with a healthy donor of the same gender and similar age. This practice helps us control for sampling biases.



   Company Address: 3 East 28th Street New York 10016 NY
   Company Phone Number: 206-0935   Stock Exchange / Ticker: NASDAQ ODT
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Leap Therapeutics Inc

Leap Therapeutics Inc Posts Operating Deficit of $14.82 Million in Latest Financial Report

Leap Therapeutics Inc, a major pharmaceutical preparations company, recently reported its financial results for the October to December 31, 2023 reporting season. While shareholders had not anticipated any significant changes, they were disappointed to observe an operating deficit of $14.82 million during this period. This represents a decline compared to the fourth quarter of 2022, when the operating deficit stood at $13.943 million.
Furthermore, the company recorded a shortfall of $12.465 million, a significant increase from the previous year's $12.102 million deficit. These figures highlight the challenging environment faced by Leap Therapeutics Inc during the specified timeframe.

Xbiotech Inc

XBITsn Holds Steady Revenue in Fourth Quarter of 2023

Xbiotech Inc., a leading biotechnology company, recently released its financial results for the fiscal period ending December 31, 2023. The company reported a loss of $0.15 per share, compared to $0.10 per share the previous year, while Income per Share improved from $0.24 to $0.00 per share from the previous quarter. Despite the losses, the company remains optimistic about its future growth prospects.
One interesting fact from the financial report is that Xbiotech Inc. realized a net shortfall of $4.635 million, which is higher than the $3.203 million reported a year ago. Additionally, the company also noted a shortfall of $24.56 million for the financial period 2023. Despite these challenges, the company is committed to innovation and advancing the frontiers of medical science.

Acurx Pharmaceuticals Inc

Acurx Pharmaceuticals Inc Faces Stock Plunge and Financial Contraction in Fiscal Fourth Quarter of 2023

Acurx Pharmaceuticals Inc, a Major Pharmaceutical Preparations company, has seen a significant drop in its stock price over the past year. The stock has dropped by -21.13% compared to a year ago, and by -35.48% in the past 90 days. Currently trading on the NASDAQ, the stock is -7.5% below its 52-week average.
The company recently reported its financial results for the period ending December 31, 2023, and shareholders have expressed concerns about the top-line performance. The operating shortfall for Acurx Pharmaceuticals Inc was at $-5.11459 million, which represents a contraction from $-3.260511 million in the fourth quarter of 2022. Analysts are closely watching to see if the company can improve its revenue numbers in the coming quarters.

Soligenix Inc

Soligenix Inc Narrows Fourth Quarter Shortfall 2.

As a financial journalist for the , I have been closely following the recent financial results of Major Pharmaceutical Preparations company, Soligenix Inc. The company's performance in the October to December 31, 2023 period has shown some improvement compared to the previous year.
In the fourth quarter of 2023, Soligenix Inc reported a net shortfall of $-1.820 million, a significant improvement from the $-11.901 million deficit in the same quarter a year ago. The company also managed to reduce its shortfall per share to $-0.17 from $-4.14 in the previous year, indicating progress in their financial performance.
Despite the positive changes, Soligenix Inc's revenue deteriorated by -11.55% from $0.95 million in the previous year. However, in the recent quarter, revenue surged by 87.682% from $0.13 million in the prior quarter, showing a promising trend for the company's future financial performance.

Eterna Therapeutics Inc

Eterna Therapeutics Inc Reports Revenue of $0.017 Million in Q4 2023 Financial Results

In the fourth quarter of 2023, Eterna Therapeutics Inc, a major pharmaceutical preparations company, disclosed revenue of $0.017 million, marking a slight increase from the previous year. However, the company also reported a net deficit of $-6.153 million for the same quarter, which was larger than the deficit of $-4.490 million in the previous year. This increase in deficit is concerning to analysts, especially as the level of accounts receivable has declined to $0.4 million, indicating a potential slowdown in demand for the company's products.
Furthermore, Eterna Therapeutics Inc indicated a net deficit of $-21.67 million for the fiscal year 2023, along with revenue of $0.07 million. Despite these challenges, the company has managed to decrease its deficit per share to $-4.08 from $-8.06 in the preceding fiscal year, showing some improvement in its financial performance.






 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com